Analysis frame
Mixed evidence
Use two separate settings to test whether computational efficiency benefits the affected person, carefully preserving different methods, denominators and uncertainty.
- Shoppers comparing grocery prices
- Biomedical researchers and future patients relying on complete evidence
- The Instacart experiment does not prove personal-data targeting and was discontinued
- Dataset-screening accuracy does not establish downstream clinical benefit
- Opaque prices could erode comparison shopping and consumer trust
- Audited screening could expand useful biomedical evidence synthesis
The price finding needs its denominator
Consumer Reports' corrected maximum was a 23% difference for one item. The experiment did not establish that personal characteristics set prices, and Instacart says it stopped the program.
The science finding needs its miss rate
The peer-reviewed study reports fast screening and high but imperfect individual-model sensitivity across its tested datasets. Independent replication and human review are needed before extrapolating to patient benefit.
Go to the source
Read the evidence behind this analysis. External links open in a new tab.
CBS News — AI and the future of posted prices Consumer Reports — corrected Instacart pricing investigation Instacart — response to the pricing study Scientific Data — biomedical dataset-screening study


